Saturday, May 28, 2005

ping?

Well, that’s like seven times now that I’ve promised to blog and haven’t. Just trying to get rid of the chaff, you know. Now the only people who check this website are googling for typo’d versions of otherwise clever phrases or people with abhorrently boring jobs. Say it with me – abhorrently – rivals ‘hemorrhage’ as far as painful words go.

Well folks, I join you in the workforce of people with oft-abhorrent jobs. At one point in my life, I’d argue that I have the silver lining of curing the world of Alzheimer’s Disease? But like a canned spiel that dies with overuse (“bizzaro” metaphors?), the curing the world b.s. died on me somewhere between college application essays and graduate school application essays. Words like ‘fascination’ and ‘exhilaration for biology’ – well they all became vague smells that remind me of more hopeful days gone by.

On that note, there’s not a hint of depression in this fine young soul. To the rest of the world, every time I post a blog entry or send out an email that’s mildly unsaccharine, I’m firing out a hearty warning to hide the sleeping pills… or Dayquil… or laxatives, or all three – man, what a combo.

So… I’m pitching a new idea here. And it’s going to come off as lame, so brace yourselves here. One thing is clear: I am about as irregular in blogging as I am without my daily dose of Metamucil (sure it’s gratuitous, but at least someday I’ll look back on this humor and feel deep shame?). OK, so now for the bad idea. I’m of the persuasion that most of my friends and/or readers are moderately clever, as some even have blogs of their own. The girlfriend even has her own blog, but that was just destiny, I’d argue. Anyhow, I’m inviting anyone (barring my mother) with anything worthwhile to say to post to this – the address is devdoot.blog at blogger dot com.

So, aside from inviting Viagra ads to my blog and taking flack for being violently unoriginal and lazy, this space might not suck if I get some guest musings. Alright.

Now, for some life updates. I’m in a lab, life is stable and slow. My personal trainer has stopped comparing me to women and now compares my strength to the goose. “You know about the goose, right?” “The goose, Troy?” “The goose can shit real quick and hard, but can’t shit for very long.” I guess that’s what happens when personal trainers meet the morally ambiguous universe of Chinese proverbs. As my strength has marginally increased, I enjoy looking at my arms at there is a noticeable twitch when I flex – there’s a real before-and-after difference, folks. (We’re talking trimspa/Jared caliber, but not the abflex dude – he has me and Jared beat hands down.) Anyhow, my fascination for my own arms gets me into trouble while I’m spotting other people. Moral: vanity kills.

OK, well if I want to keep this regular, I’ll save summore for tomorrow. And there will be a tomorrow… before August at least.
Hah?

6 Comments:

Blogger dunadan67 said...

yes

8:26 PM  
Anonymous Anonymous said...

haha! GOOSE! I can prolly suplex u.

10:20 PM  
Anonymous Anonymous said...

Pong!

So how much do you bench press?

Gevorg.

1:22 AM  
Anonymous Anonymous said...

make another post. it's been a while.

2:37 AM  
Blogger sixty-seven said...

you lie.

12:38 AM  
Blogger wbea07asqr said...

Big News From The Healthcare Industry!!

+++++++++++Current Profile+++++++++++
Faceprint Global Solutions (FCPG)
Current Price $0.15
A company with hot new identity solution products
and licenses with over 40 current governmental and
non-governmental contracts in negotiations.
+++++++++++++++++++++++++++++++++

Is this an undiscovered gem priced to go higher!!
Please read the following Announcement in its Entirety and Consider the Possibilities�
Watch this One to Trade!

FCPG volume trading is beginning to surge with this landslide Announcement. The value of this
stock appears poised for growth! This one should not remain on the ground floor for long.

BREAKING NEWS!!

Faceprint Global Solutions (FCPG) is pleased to announce that its European partner, Keyvelop, has teamed up with IBM's Partner World Industry Networks to deliver customer software requirement solutions for the international healthcare industry.
With FGS owning the exclusive North American rights to distribute the worlds leading encryption and transmission software developed by Keyvelop, FGS is poised to capture large volumes of sales generated by customers currently using IBM's software in the healthcare and other industries.
With traceability and security now deemed a serious business priority, companies are increasingly focused on employing procedures and controls designed to ensure the authenticity, integrity and confidentiality of electronic records.
"This is a very positive move for FGS and for Keyvelop," said FGS CEO Pierre Cote. "We are very happy about the decision to go with IBM. This is a continuation of the progress made by everyone associated with FGS and its partners."
Buell Duncan, IBM's general manager of ISV & Developer Relations commented, "Collaborating with Keyvelop will ensure that we develop open solutions that are easy to maintain and cost effective for our customers in the healthcare and life sciences industry."
Among other things, this new software technology which is currently being used by a number of European healthcare companies, is used to send any file, regardless of format or size. Encryption keys, evidence of transmission integrity with fingerprint calculation, time-stamping of all actions and status record updating, pre-checking sender and receiver identities, validating file opening dates are part of Keyvelop features.
About FacePrint Global Solutions, Inc.
FGS operates a business, which develops and delivers a variety of technology solutions, including biometric software applications on smart cards and other support mediums (apometric solutions). FGS's products provide biometric solutions for identity authentication and a host of smart card- and biometrics-related hardware peripherals and software applications. Apometrix, FGS's wholly-owned subsidiary, combines on-card or in-chip multi-application management solutions with best-of-breed 'in-card matching' biometrics. Keyvelop's secure digital envelope solution and Apometrix's on-card biometrics work together to produce the winning combination in the fields of security, traceability and identity management. FGS is headquartered in Fresno, California.
Conclusion:

The examples above show the Awesome, Earning Potential of little known Companies That Explode onto Investor's Radar Screens. This stock will not be a Secret for long. Then You May Feel the Desire to Act Right Now! And Please Watch This One Trade!
GO FCPG!

All statements made are our express opinion only and should be treated as such. We may own, take position and sell any securities mentioned at any time. Any statements that express or involve discussions with respect to predictions, goals, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. This profile is in no way affiliated with the featured company. We were compensated one thousand dollars from third party (IR Marketing) to distribute this report. Forward looking statements in this action may be identified through the use of words such as: "projects", "foresee", "expects". in compliance with Section 17(b), we disclose the holding of FGS shares prior to the publication of this report. Be aware of an inherent conflict of interest resulting from such holdings due to our intent to profit from the liquidation of these shares. Shares may be sold at any time, even after positive statements have been made regarding the above company. Since we own shares, there is an inherent conflict of interest in our statements and opinions. Readers of this publication are cautioned not to place undue reliance on forward-looking statements, which are based on certain assumptions and expectations involving various risks and uncertainties that could cause results to differ materially from those set forth in the forward- looking statements. This is not solicitation to buy or sell stocks, this text is for informational purpose only and you should seek professional advice from registered financial advisor before you do anything related with buying or selling stocks, penny stocks are very high risk and you can lose your entire investment.

2:52 AM  

Post a Comment

<< Home